Baseline Metabolic Tumor Volume and Total Lesion Glycolysis Are Associated With Survival Outcomes in Patients With Locally Advanced Pancreatic Cancer Receiving Stereotactic Body Radiation Therapy
Purpose Although previous studies have demonstrated the prognostic value of positron emission tomography (PET) parameters in other malignancies, the role of PET in pancreatic cancer has yet to be well established. We analyzed the prognostic utility of PET for patients with locally advanced pancreati...
Gespeichert in:
| Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2014-07, Vol.89 (3), p.539-546 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 546 |
|---|---|
| container_issue | 3 |
| container_start_page | 539 |
| container_title | International journal of radiation oncology, biology, physics |
| container_volume | 89 |
| creator | Dholakia, Avani S., BS Chaudhry, Muhammad, MD Leal, Jeffrey P., BA Chang, Daniel T., MD Raman, Siva P., MD Hacker-Prietz, Amy, PA-C Su, Zheng, PhD Pai, Jonathan, BA Oteiza, Katharine E., MS Griffith, Mary E., BSN Wahl, Richard L., MD Tryggestad, Erik, PhD Pawlik, Timothy, MD, MBA Laheru, Daniel A., MD Wolfgang, Christopher L., MD, PhD Koong, Albert C., MD, PhD Herman, Joseph M., MD, MSc |
| description | Purpose Although previous studies have demonstrated the prognostic value of positron emission tomography (PET) parameters in other malignancies, the role of PET in pancreatic cancer has yet to be well established. We analyzed the prognostic utility of PET for patients with locally advanced pancreatic cancer (LAPC) undergoing fractionated stereotactic body radiation therapy (SBRT). Materials and Methods Thirty-two patients with LAPC in a prospective clinical trial received up to 3 doses of gemcitabine, followed by 33 Gy in 5 fractions of 6.6 Gy, using SBRT. All patients received a baseline PET scan prior to SBRT (pre-SBRT PET). Metabolic tumor volume (MTV), total lesion glycolysis (TLG), and maximum and peak standardized uptake values (SUVmax and SUVpeak ) on pre-SBRT PET scans were calculated using custom-designed software. Disease was measured at a threshold based on the liver SUV, using the equation Livermean + [2 × Liversd ]. Median values of PET parameters were used as cutoffs when assessing their prognostic potential through Cox regression analyses. Results Of the 32 patients, the majority were male (n=19, 59%), 65 years or older (n=21, 66%), and had tumors located in the pancreatic head (n=27, 84%). Twenty-seven patients (84%) received induction gemcitabine prior to SBRT. Median overall survival for the entire cohort was 18.8 months (95% confidence interval [CI], 15.7-22.0). An MTV of 26.8 cm3 or greater (hazard ratio [HR] 4.46, 95% CI 1.64-5.88, P |
| doi_str_mv | 10.1016/j.ijrobp.2014.02.031 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4372085</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0360301614002752</els_id><sourcerecordid>1687663678</sourcerecordid><originalsourceid>FETCH-LOGICAL-c579t-35176a67fd0fc151141339b394e6423eddab74c54e67bac41b4d6cd6cb2f13403</originalsourceid><addsrcrecordid>eNqFUttuEzEQXSEQLYU_QMgSL7wk-Lbr5AUpjaAgBbVqwuXN8nonjYPXDrZ3pf0bvgXxYXiVUi4vSJZGts-cOTNziuIpwVOCSfVyPzX74OvDlGLCp5hOMSP3ilMyE_MJK8vP94tTzCo8YRl8UjyKcY8xJkTwh8UJ5aIknODT4se5imCNA_Qekqq9NRptutYH9NHbrgWkXIM2PimLVhCNd-jCDtrbIZqIFgHQIkavjUrQoE8m7dC6C73pM_yyS9q3EJFx379dqWTApXjErLxW1g5o0fTK6Zx5lUOAjNFoOb4EdA0aTG_cDVonCJAF6PH33DcDulZNLjhq2ewgqMPwuHiwVTbCk9t4Vnx483qzfDtZXV68Wy5WE12KecpTIaJSldg2eKtJSfIEGJvXbM6h4pRB06hacF3mq6iV5qTmTaXzqemWMI7ZWfHqyHvo6hYanTsKyspDMK0Kg_TKyL9_nNnJG99LzgTFszITPD8S-JiMjNok0DvtnQOdJKWcYsZmGfXitkzwXzuISbYmarBWOfBdlKSaiapilRih_AjVwccYYHsnhmA52kTu5dEmcrSJxFRmm-S0Z382cpf0yxe_O4U8zt5AGMXCuCsTRq2NN_-r8C-Bzi4zee9fYIC4911weVWSyJgT5Hq06uhUwjGmoqTsJ6LJ6qY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1687663678</pqid></control><display><type>article</type><title>Baseline Metabolic Tumor Volume and Total Lesion Glycolysis Are Associated With Survival Outcomes in Patients With Locally Advanced Pancreatic Cancer Receiving Stereotactic Body Radiation Therapy</title><source>MEDLINE</source><source>ScienceDirect Freedom Collection (Elsevier)</source><creator>Dholakia, Avani S., BS ; Chaudhry, Muhammad, MD ; Leal, Jeffrey P., BA ; Chang, Daniel T., MD ; Raman, Siva P., MD ; Hacker-Prietz, Amy, PA-C ; Su, Zheng, PhD ; Pai, Jonathan, BA ; Oteiza, Katharine E., MS ; Griffith, Mary E., BSN ; Wahl, Richard L., MD ; Tryggestad, Erik, PhD ; Pawlik, Timothy, MD, MBA ; Laheru, Daniel A., MD ; Wolfgang, Christopher L., MD, PhD ; Koong, Albert C., MD, PhD ; Herman, Joseph M., MD, MSc</creator><creatorcontrib>Dholakia, Avani S., BS ; Chaudhry, Muhammad, MD ; Leal, Jeffrey P., BA ; Chang, Daniel T., MD ; Raman, Siva P., MD ; Hacker-Prietz, Amy, PA-C ; Su, Zheng, PhD ; Pai, Jonathan, BA ; Oteiza, Katharine E., MS ; Griffith, Mary E., BSN ; Wahl, Richard L., MD ; Tryggestad, Erik, PhD ; Pawlik, Timothy, MD, MBA ; Laheru, Daniel A., MD ; Wolfgang, Christopher L., MD, PhD ; Koong, Albert C., MD, PhD ; Herman, Joseph M., MD, MSc</creatorcontrib><description>Purpose Although previous studies have demonstrated the prognostic value of positron emission tomography (PET) parameters in other malignancies, the role of PET in pancreatic cancer has yet to be well established. We analyzed the prognostic utility of PET for patients with locally advanced pancreatic cancer (LAPC) undergoing fractionated stereotactic body radiation therapy (SBRT). Materials and Methods Thirty-two patients with LAPC in a prospective clinical trial received up to 3 doses of gemcitabine, followed by 33 Gy in 5 fractions of 6.6 Gy, using SBRT. All patients received a baseline PET scan prior to SBRT (pre-SBRT PET). Metabolic tumor volume (MTV), total lesion glycolysis (TLG), and maximum and peak standardized uptake values (SUVmax and SUVpeak ) on pre-SBRT PET scans were calculated using custom-designed software. Disease was measured at a threshold based on the liver SUV, using the equation Livermean + [2 × Liversd ]. Median values of PET parameters were used as cutoffs when assessing their prognostic potential through Cox regression analyses. Results Of the 32 patients, the majority were male (n=19, 59%), 65 years or older (n=21, 66%), and had tumors located in the pancreatic head (n=27, 84%). Twenty-seven patients (84%) received induction gemcitabine prior to SBRT. Median overall survival for the entire cohort was 18.8 months (95% confidence interval [CI], 15.7-22.0). An MTV of 26.8 cm3 or greater (hazard ratio [HR] 4.46, 95% CI 1.64-5.88, P <.003) and TLG of 70.9 or greater (HR 3.08, 95% CI 1.18-8.02, P <.021) on pre-SBRT PET scan were associated with inferior overall survival on univariate analysis. Both pre-SBRT MTV (HR 5.13, 95% CI 1.19-22.21, P =.029) and TLG (HR 3.34, 95% CI 1.07-10.48, P =.038) remained independently associated with overall survival in separate multivariate analyses. Conclusions Pre-SBRT MTV and TLG are potential predictive factors for overall survival in patients with LAPC and may assist in tailoring therapy.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2014.02.031</identifier><identifier>PMID: 24751410</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Antimetabolites, Antineoplastic - therapeutic use ; Blood Glucose - analysis ; Carcinoma, Pancreatic Ductal - diagnostic imaging ; Carcinoma, Pancreatic Ductal - metabolism ; Carcinoma, Pancreatic Ductal - mortality ; Carcinoma, Pancreatic Ductal - pathology ; Carcinoma, Pancreatic Ductal - surgery ; CLINICAL TRIALS ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - therapeutic use ; Dose Fractionation ; Drug Administration Schedule ; Female ; Fluorodeoxyglucose F18 ; GLYCOLYSIS ; HAZARDS ; Hematology, Oncology and Palliative Medicine ; Humans ; Induction Chemotherapy ; LIVER ; Liver - diagnostic imaging ; Male ; Middle Aged ; Multimodal Imaging - methods ; MULTIVARIATE ANALYSIS ; NEOPLASMS ; PANCREAS ; Pancreatic Neoplasms - diagnostic imaging ; Pancreatic Neoplasms - metabolism ; Pancreatic Neoplasms - mortality ; Pancreatic Neoplasms - pathology ; Pancreatic Neoplasms - surgery ; PATIENTS ; POSITRON COMPUTED TOMOGRAPHY ; Positron-Emission Tomography ; Prognosis ; Prospective Studies ; RADIATION DOSES ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; Radiopharmaceuticals ; Radiosurgery ; RADIOTHERAPY ; Regression Analysis ; Tomography, X-Ray Computed ; Tumor Burden ; UPTAKE</subject><ispartof>International journal of radiation oncology, biology, physics, 2014-07, Vol.89 (3), p.539-546</ispartof><rights>Elsevier Inc.</rights><rights>2014 Elsevier Inc.</rights><rights>Copyright © 2014 Elsevier Inc. All rights reserved.</rights><rights>2014 Elsevier Inc. All rights reserved. 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c579t-35176a67fd0fc151141339b394e6423eddab74c54e67bac41b4d6cd6cb2f13403</citedby><cites>FETCH-LOGICAL-c579t-35176a67fd0fc151141339b394e6423eddab74c54e67bac41b4d6cd6cb2f13403</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijrobp.2014.02.031$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24751410$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22420338$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Dholakia, Avani S., BS</creatorcontrib><creatorcontrib>Chaudhry, Muhammad, MD</creatorcontrib><creatorcontrib>Leal, Jeffrey P., BA</creatorcontrib><creatorcontrib>Chang, Daniel T., MD</creatorcontrib><creatorcontrib>Raman, Siva P., MD</creatorcontrib><creatorcontrib>Hacker-Prietz, Amy, PA-C</creatorcontrib><creatorcontrib>Su, Zheng, PhD</creatorcontrib><creatorcontrib>Pai, Jonathan, BA</creatorcontrib><creatorcontrib>Oteiza, Katharine E., MS</creatorcontrib><creatorcontrib>Griffith, Mary E., BSN</creatorcontrib><creatorcontrib>Wahl, Richard L., MD</creatorcontrib><creatorcontrib>Tryggestad, Erik, PhD</creatorcontrib><creatorcontrib>Pawlik, Timothy, MD, MBA</creatorcontrib><creatorcontrib>Laheru, Daniel A., MD</creatorcontrib><creatorcontrib>Wolfgang, Christopher L., MD, PhD</creatorcontrib><creatorcontrib>Koong, Albert C., MD, PhD</creatorcontrib><creatorcontrib>Herman, Joseph M., MD, MSc</creatorcontrib><title>Baseline Metabolic Tumor Volume and Total Lesion Glycolysis Are Associated With Survival Outcomes in Patients With Locally Advanced Pancreatic Cancer Receiving Stereotactic Body Radiation Therapy</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose Although previous studies have demonstrated the prognostic value of positron emission tomography (PET) parameters in other malignancies, the role of PET in pancreatic cancer has yet to be well established. We analyzed the prognostic utility of PET for patients with locally advanced pancreatic cancer (LAPC) undergoing fractionated stereotactic body radiation therapy (SBRT). Materials and Methods Thirty-two patients with LAPC in a prospective clinical trial received up to 3 doses of gemcitabine, followed by 33 Gy in 5 fractions of 6.6 Gy, using SBRT. All patients received a baseline PET scan prior to SBRT (pre-SBRT PET). Metabolic tumor volume (MTV), total lesion glycolysis (TLG), and maximum and peak standardized uptake values (SUVmax and SUVpeak ) on pre-SBRT PET scans were calculated using custom-designed software. Disease was measured at a threshold based on the liver SUV, using the equation Livermean + [2 × Liversd ]. Median values of PET parameters were used as cutoffs when assessing their prognostic potential through Cox regression analyses. Results Of the 32 patients, the majority were male (n=19, 59%), 65 years or older (n=21, 66%), and had tumors located in the pancreatic head (n=27, 84%). Twenty-seven patients (84%) received induction gemcitabine prior to SBRT. Median overall survival for the entire cohort was 18.8 months (95% confidence interval [CI], 15.7-22.0). An MTV of 26.8 cm3 or greater (hazard ratio [HR] 4.46, 95% CI 1.64-5.88, P <.003) and TLG of 70.9 or greater (HR 3.08, 95% CI 1.18-8.02, P <.021) on pre-SBRT PET scan were associated with inferior overall survival on univariate analysis. Both pre-SBRT MTV (HR 5.13, 95% CI 1.19-22.21, P =.029) and TLG (HR 3.34, 95% CI 1.07-10.48, P =.038) remained independently associated with overall survival in separate multivariate analyses. Conclusions Pre-SBRT MTV and TLG are potential predictive factors for overall survival in patients with LAPC and may assist in tailoring therapy.</description><subject>Aged</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Blood Glucose - analysis</subject><subject>Carcinoma, Pancreatic Ductal - diagnostic imaging</subject><subject>Carcinoma, Pancreatic Ductal - metabolism</subject><subject>Carcinoma, Pancreatic Ductal - mortality</subject><subject>Carcinoma, Pancreatic Ductal - pathology</subject><subject>Carcinoma, Pancreatic Ductal - surgery</subject><subject>CLINICAL TRIALS</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Deoxycytidine - therapeutic use</subject><subject>Dose Fractionation</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>GLYCOLYSIS</subject><subject>HAZARDS</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Induction Chemotherapy</subject><subject>LIVER</subject><subject>Liver - diagnostic imaging</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multimodal Imaging - methods</subject><subject>MULTIVARIATE ANALYSIS</subject><subject>NEOPLASMS</subject><subject>PANCREAS</subject><subject>Pancreatic Neoplasms - diagnostic imaging</subject><subject>Pancreatic Neoplasms - metabolism</subject><subject>Pancreatic Neoplasms - mortality</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pancreatic Neoplasms - surgery</subject><subject>PATIENTS</subject><subject>POSITRON COMPUTED TOMOGRAPHY</subject><subject>Positron-Emission Tomography</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>RADIATION DOSES</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>Radiopharmaceuticals</subject><subject>Radiosurgery</subject><subject>RADIOTHERAPY</subject><subject>Regression Analysis</subject><subject>Tomography, X-Ray Computed</subject><subject>Tumor Burden</subject><subject>UPTAKE</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFUttuEzEQXSEQLYU_QMgSL7wk-Lbr5AUpjaAgBbVqwuXN8nonjYPXDrZ3pf0bvgXxYXiVUi4vSJZGts-cOTNziuIpwVOCSfVyPzX74OvDlGLCp5hOMSP3ilMyE_MJK8vP94tTzCo8YRl8UjyKcY8xJkTwh8UJ5aIknODT4se5imCNA_Qekqq9NRptutYH9NHbrgWkXIM2PimLVhCNd-jCDtrbIZqIFgHQIkavjUrQoE8m7dC6C73pM_yyS9q3EJFx379dqWTApXjErLxW1g5o0fTK6Zx5lUOAjNFoOb4EdA0aTG_cDVonCJAF6PH33DcDulZNLjhq2ewgqMPwuHiwVTbCk9t4Vnx483qzfDtZXV68Wy5WE12KecpTIaJSldg2eKtJSfIEGJvXbM6h4pRB06hacF3mq6iV5qTmTaXzqemWMI7ZWfHqyHvo6hYanTsKyspDMK0Kg_TKyL9_nNnJG99LzgTFszITPD8S-JiMjNok0DvtnQOdJKWcYsZmGfXitkzwXzuISbYmarBWOfBdlKSaiapilRih_AjVwccYYHsnhmA52kTu5dEmcrSJxFRmm-S0Z382cpf0yxe_O4U8zt5AGMXCuCsTRq2NN_-r8C-Bzi4zee9fYIC4911weVWSyJgT5Hq06uhUwjGmoqTsJ6LJ6qY</recordid><startdate>20140701</startdate><enddate>20140701</enddate><creator>Dholakia, Avani S., BS</creator><creator>Chaudhry, Muhammad, MD</creator><creator>Leal, Jeffrey P., BA</creator><creator>Chang, Daniel T., MD</creator><creator>Raman, Siva P., MD</creator><creator>Hacker-Prietz, Amy, PA-C</creator><creator>Su, Zheng, PhD</creator><creator>Pai, Jonathan, BA</creator><creator>Oteiza, Katharine E., MS</creator><creator>Griffith, Mary E., BSN</creator><creator>Wahl, Richard L., MD</creator><creator>Tryggestad, Erik, PhD</creator><creator>Pawlik, Timothy, MD, MBA</creator><creator>Laheru, Daniel A., MD</creator><creator>Wolfgang, Christopher L., MD, PhD</creator><creator>Koong, Albert C., MD, PhD</creator><creator>Herman, Joseph M., MD, MSc</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>C1K</scope><scope>OTOTI</scope><scope>5PM</scope></search><sort><creationdate>20140701</creationdate><title>Baseline Metabolic Tumor Volume and Total Lesion Glycolysis Are Associated With Survival Outcomes in Patients With Locally Advanced Pancreatic Cancer Receiving Stereotactic Body Radiation Therapy</title><author>Dholakia, Avani S., BS ; Chaudhry, Muhammad, MD ; Leal, Jeffrey P., BA ; Chang, Daniel T., MD ; Raman, Siva P., MD ; Hacker-Prietz, Amy, PA-C ; Su, Zheng, PhD ; Pai, Jonathan, BA ; Oteiza, Katharine E., MS ; Griffith, Mary E., BSN ; Wahl, Richard L., MD ; Tryggestad, Erik, PhD ; Pawlik, Timothy, MD, MBA ; Laheru, Daniel A., MD ; Wolfgang, Christopher L., MD, PhD ; Koong, Albert C., MD, PhD ; Herman, Joseph M., MD, MSc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c579t-35176a67fd0fc151141339b394e6423eddab74c54e67bac41b4d6cd6cb2f13403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Blood Glucose - analysis</topic><topic>Carcinoma, Pancreatic Ductal - diagnostic imaging</topic><topic>Carcinoma, Pancreatic Ductal - metabolism</topic><topic>Carcinoma, Pancreatic Ductal - mortality</topic><topic>Carcinoma, Pancreatic Ductal - pathology</topic><topic>Carcinoma, Pancreatic Ductal - surgery</topic><topic>CLINICAL TRIALS</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Deoxycytidine - therapeutic use</topic><topic>Dose Fractionation</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>GLYCOLYSIS</topic><topic>HAZARDS</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Induction Chemotherapy</topic><topic>LIVER</topic><topic>Liver - diagnostic imaging</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multimodal Imaging - methods</topic><topic>MULTIVARIATE ANALYSIS</topic><topic>NEOPLASMS</topic><topic>PANCREAS</topic><topic>Pancreatic Neoplasms - diagnostic imaging</topic><topic>Pancreatic Neoplasms - metabolism</topic><topic>Pancreatic Neoplasms - mortality</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pancreatic Neoplasms - surgery</topic><topic>PATIENTS</topic><topic>POSITRON COMPUTED TOMOGRAPHY</topic><topic>Positron-Emission Tomography</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>RADIATION DOSES</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>Radiopharmaceuticals</topic><topic>Radiosurgery</topic><topic>RADIOTHERAPY</topic><topic>Regression Analysis</topic><topic>Tomography, X-Ray Computed</topic><topic>Tumor Burden</topic><topic>UPTAKE</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dholakia, Avani S., BS</creatorcontrib><creatorcontrib>Chaudhry, Muhammad, MD</creatorcontrib><creatorcontrib>Leal, Jeffrey P., BA</creatorcontrib><creatorcontrib>Chang, Daniel T., MD</creatorcontrib><creatorcontrib>Raman, Siva P., MD</creatorcontrib><creatorcontrib>Hacker-Prietz, Amy, PA-C</creatorcontrib><creatorcontrib>Su, Zheng, PhD</creatorcontrib><creatorcontrib>Pai, Jonathan, BA</creatorcontrib><creatorcontrib>Oteiza, Katharine E., MS</creatorcontrib><creatorcontrib>Griffith, Mary E., BSN</creatorcontrib><creatorcontrib>Wahl, Richard L., MD</creatorcontrib><creatorcontrib>Tryggestad, Erik, PhD</creatorcontrib><creatorcontrib>Pawlik, Timothy, MD, MBA</creatorcontrib><creatorcontrib>Laheru, Daniel A., MD</creatorcontrib><creatorcontrib>Wolfgang, Christopher L., MD, PhD</creatorcontrib><creatorcontrib>Koong, Albert C., MD, PhD</creatorcontrib><creatorcontrib>Herman, Joseph M., MD, MSc</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>OSTI.GOV</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dholakia, Avani S., BS</au><au>Chaudhry, Muhammad, MD</au><au>Leal, Jeffrey P., BA</au><au>Chang, Daniel T., MD</au><au>Raman, Siva P., MD</au><au>Hacker-Prietz, Amy, PA-C</au><au>Su, Zheng, PhD</au><au>Pai, Jonathan, BA</au><au>Oteiza, Katharine E., MS</au><au>Griffith, Mary E., BSN</au><au>Wahl, Richard L., MD</au><au>Tryggestad, Erik, PhD</au><au>Pawlik, Timothy, MD, MBA</au><au>Laheru, Daniel A., MD</au><au>Wolfgang, Christopher L., MD, PhD</au><au>Koong, Albert C., MD, PhD</au><au>Herman, Joseph M., MD, MSc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Baseline Metabolic Tumor Volume and Total Lesion Glycolysis Are Associated With Survival Outcomes in Patients With Locally Advanced Pancreatic Cancer Receiving Stereotactic Body Radiation Therapy</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2014-07-01</date><risdate>2014</risdate><volume>89</volume><issue>3</issue><spage>539</spage><epage>546</epage><pages>539-546</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><abstract>Purpose Although previous studies have demonstrated the prognostic value of positron emission tomography (PET) parameters in other malignancies, the role of PET in pancreatic cancer has yet to be well established. We analyzed the prognostic utility of PET for patients with locally advanced pancreatic cancer (LAPC) undergoing fractionated stereotactic body radiation therapy (SBRT). Materials and Methods Thirty-two patients with LAPC in a prospective clinical trial received up to 3 doses of gemcitabine, followed by 33 Gy in 5 fractions of 6.6 Gy, using SBRT. All patients received a baseline PET scan prior to SBRT (pre-SBRT PET). Metabolic tumor volume (MTV), total lesion glycolysis (TLG), and maximum and peak standardized uptake values (SUVmax and SUVpeak ) on pre-SBRT PET scans were calculated using custom-designed software. Disease was measured at a threshold based on the liver SUV, using the equation Livermean + [2 × Liversd ]. Median values of PET parameters were used as cutoffs when assessing their prognostic potential through Cox regression analyses. Results Of the 32 patients, the majority were male (n=19, 59%), 65 years or older (n=21, 66%), and had tumors located in the pancreatic head (n=27, 84%). Twenty-seven patients (84%) received induction gemcitabine prior to SBRT. Median overall survival for the entire cohort was 18.8 months (95% confidence interval [CI], 15.7-22.0). An MTV of 26.8 cm3 or greater (hazard ratio [HR] 4.46, 95% CI 1.64-5.88, P <.003) and TLG of 70.9 or greater (HR 3.08, 95% CI 1.18-8.02, P <.021) on pre-SBRT PET scan were associated with inferior overall survival on univariate analysis. Both pre-SBRT MTV (HR 5.13, 95% CI 1.19-22.21, P =.029) and TLG (HR 3.34, 95% CI 1.07-10.48, P =.038) remained independently associated with overall survival in separate multivariate analyses. Conclusions Pre-SBRT MTV and TLG are potential predictive factors for overall survival in patients with LAPC and may assist in tailoring therapy.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>24751410</pmid><doi>10.1016/j.ijrobp.2014.02.031</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0360-3016 |
| ispartof | International journal of radiation oncology, biology, physics, 2014-07, Vol.89 (3), p.539-546 |
| issn | 0360-3016 1879-355X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4372085 |
| source | MEDLINE; ScienceDirect Freedom Collection (Elsevier) |
| subjects | Aged Antimetabolites, Antineoplastic - therapeutic use Blood Glucose - analysis Carcinoma, Pancreatic Ductal - diagnostic imaging Carcinoma, Pancreatic Ductal - metabolism Carcinoma, Pancreatic Ductal - mortality Carcinoma, Pancreatic Ductal - pathology Carcinoma, Pancreatic Ductal - surgery CLINICAL TRIALS Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Dose Fractionation Drug Administration Schedule Female Fluorodeoxyglucose F18 GLYCOLYSIS HAZARDS Hematology, Oncology and Palliative Medicine Humans Induction Chemotherapy LIVER Liver - diagnostic imaging Male Middle Aged Multimodal Imaging - methods MULTIVARIATE ANALYSIS NEOPLASMS PANCREAS Pancreatic Neoplasms - diagnostic imaging Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Pancreatic Neoplasms - surgery PATIENTS POSITRON COMPUTED TOMOGRAPHY Positron-Emission Tomography Prognosis Prospective Studies RADIATION DOSES Radiology RADIOLOGY AND NUCLEAR MEDICINE Radiopharmaceuticals Radiosurgery RADIOTHERAPY Regression Analysis Tomography, X-Ray Computed Tumor Burden UPTAKE |
| title | Baseline Metabolic Tumor Volume and Total Lesion Glycolysis Are Associated With Survival Outcomes in Patients With Locally Advanced Pancreatic Cancer Receiving Stereotactic Body Radiation Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T06%3A07%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Baseline%20Metabolic%20Tumor%20Volume%20and%20Total%20Lesion%20Glycolysis%20Are%20Associated%20With%20Survival%20Outcomes%20in%C2%A0Patients%20With%20Locally%20Advanced%20Pancreatic%20Cancer%20Receiving%20Stereotactic%20Body%20Radiation%20Therapy&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Dholakia,%20Avani%20S.,%20BS&rft.date=2014-07-01&rft.volume=89&rft.issue=3&rft.spage=539&rft.epage=546&rft.pages=539-546&rft.issn=0360-3016&rft.eissn=1879-355X&rft_id=info:doi/10.1016/j.ijrobp.2014.02.031&rft_dat=%3Cproquest_pubme%3E1687663678%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1687663678&rft_id=info:pmid/24751410&rft_els_id=1_s2_0_S0360301614002752&rfr_iscdi=true |